In this study, we have employed cells lines that express wild-type K-Ras (A2780 ovarian cancer cells and H1299 non-small cell lung cancer cells [57,58]), and MEK inhibition leads to a localised decrease in RhoA activity, most likely due to a spatially restricted increase in Rac activation at the leading edge (Fig 3E–3I). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.